Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Study Overview: Novo Nordisk recently completed a study titled ‘Efficacy ...

Novo Nordisk has the potential to maintain more consistent revenue growth throughout next year. There is an indication that ...

Researchers adjusted for confounders like age, hypertension, cardiovascular disease, and other comorbidities. The refined results indicated GLP-1 users had a 16% lower risk of developing epilepsy ...

In an exclusive interaction with NDTV, Managing Director of Novo Nordisk India, Vikrant Shrotriya, said the launch of ...